Economic Impact and Clinical Outcomes of Omalizumab Add-On Therapy for Patients with Severe Persistent Asthma: A Real-World Study

Luis Manuel Entrenas Costa (), Francisco Casas-Maldonado, José Gregorio Soto Campos, Alicia Padilla-Galo, Alberto Levy, Francisco Javier Álvarez Gutiérrez, Ana P. Gómez-Bastero Fernández, Concepción Morales-García, Rocío Gallego Domínguez, Gustavo Villegas Sánchez, Luis Mateos Caballero, Antonio Pereira-Vega, Cayo García Polo, Gerardo Pérez Chica and Juan José Martín Villasclaras
Additional contact information
Luis Manuel Entrenas Costa: Unidad de Gestión Clínica de Neumología, Hospital Universitario Reina Sofía, IMIBIC, Universidad de Córdoba
Francisco Casas-Maldonado: Unidad de Gestión Clínica de Neumología, Hospital Universitario San Cecilio
José Gregorio Soto Campos: Unidad de Gestión Clínica de Neumología y Alergia, Hospital de Jerez, Jerez de la Frontera
Alicia Padilla-Galo: Agencia Sanitaria Costa del Sol, Unidad de Neumología
Alberto Levy: Hospital Clínico Virgen de la Victoria
Francisco Javier Álvarez Gutiérrez: Unidad de Asma, UMQER, Hospital Universitario Virgen del Rocío
Ana P. Gómez-Bastero Fernández: Unidad de Gestión Clínica de Neumología del Hospital Universitario Virgen Macarena
Concepción Morales-García: Unidad de Gestión Clínica de Neumología, Hospital Universitario Virgen de las Nieves
Rocío Gallego Domínguez: Sección de Neumología, Complejo Hospitalario Universitario de Cáceres
Gustavo Villegas Sánchez: Unidad de Gestión Clínica de Neumología y Alergia, Hospital Torrecárdenas
Luis Mateos Caballero: Sección de Neumología, Hospital de Mérida
Antonio Pereira-Vega: Unidad de Gestión Clínica de Neumología y Alergia, Hospital Juan Ramón Jiménez
Cayo García Polo: Unidad de Gestión Clínica de Neumología, Alergia y Cirugía Torácica, Hospital Universitario Puerta del Mar
Gerardo Pérez Chica: Unidad de Gestión Clínica de Aparato Respiratorio, Hospital Médico Quirúrgico
Juan José Martín Villasclaras: Unidad Médico Quirúrgica de Enfermedades Respiratorias, Hospital Regional Universitario de Málaga

PharmacoEconomics - Open, 2019, vol. 3, issue 3, No 7, 333-342

Abstract: Abstract Background Omalizumab is a fully humanized monoclonal antibody indicated as add-on therapy to improve asthma control in patients with severe persistent allergic asthma. Aims The aim of this study was to evaluate social, healthcare expenditure and clinical outcomes changes after incorporating omalizumab into standard treatment in the control of severe asthma. Methods In this multicentre retrospective study, a total of 220 patients were included from 15 respiratory medicine departments in the regions of Andalusia and Extremadura (Spain). Effectiveness was calculated as a 3-point increase in the Asthma Control Test (ACT) and a reduction in the annual number of exacerbations. The economic evaluation included both direct and indirect costs. Incremental cost-effectiveness ratio (ICER) was calculated. Results from the year before and the year after incorporation of omalizumab were compared. Results After adding omalizumab, improvement of lung function, asthma and rhinitis according to patient perception, as well as the number of exacerbations and asthma control measured by the ACT score were observed. Globally, both healthcare resources and pharmacological costs decreased after omalizumab treatment, excluding omalizumab cost. When only direct costs were considered, the ICER was €1712 (95% CI 1487–1995) per avoided exacerbation and €3859 (95% CI 3327–4418) for every 3-point increase in the ACT score. When both direct and indirect costs were considered, the ICER was €1607 (95% CI 1385–1885) for every avoided exacerbation and €3555 (95% CI 3012–4125) for every 3-point increase. Conclusions Omalizumab was shown to be an effective add-on therapy for patients with persistent severe asthma and allowed reducing key drivers of asthma-related costs.

Date: 2019
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s41669-019-0117-4 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharmo:v:3:y:2019:i:3:d:10.1007_s41669-019-0117-4

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/41669

DOI: 10.1007/s41669-019-0117-4

Access Statistics for this article

PharmacoEconomics - Open is currently edited by Timothy Wrightson and Christopher Carswell

More articles in PharmacoEconomics - Open from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().